Haleon plc Files Form 6-K Reporting Holdings
Ticker: HLNCF · Form: 6-K · Filed: Oct 4, 2024 · CIK: 1900304
Sentiment: neutral
Topics: disclosure, foreign-private-issuer, holdings
TL;DR
Haleon filed a 6-K on Oct 4th about company holdings. No major news, just a standard disclosure.
AI Summary
On October 4, 2024, Haleon plc filed a Form 6-K, reporting holdings in the company. This filing is a routine report for foreign private issuers and does not contain specific financial figures or significant business updates beyond the notification of holdings.
Why It Matters
This filing serves as a notification to investors and regulators about changes or existing significant holdings in Haleon plc, ensuring transparency in share ownership.
Risk Assessment
Risk Level: low — The filing is a routine disclosure for a foreign private issuer and does not contain information that would typically impact the company's risk profile.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former Company Name
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the filer?
The filer is Haleon plc.
What is the date of the report?
The report is for the month of October 2024, with the specific filing date being October 4, 2024.
What is the primary content of Exhibit 99.1?
Exhibit 99.1 is titled 'Holding(s) in Company' and is dated 04 October 2024.
Does Haleon plc file annual reports under Form 20-F or 40-F?
Haleon plc indicates it files annual reports under Form 20-F.
Filing Stats: 884 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-10-04 09:44:47
Filing Documents
- a0458h.htm (6-K) — 62KB
- 0001654954-24-012703.txt ( ) — 63KB
From the Filing
(S) IN COMPANY a0458h UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of October 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  04 October 2024 - “Holding(s) in Company”     99.1     4 October 2024   HALEON PLC   ("Haleon" or "the Company")      TR-1: Standard form for notification of major holdings   1. Issuer Details   ISIN GB00BMX86B70   Issuer Name HALEON PLC   UK or Non-UK Issuer UK   2. Reason for Notification An acquisition or disposal of voting rights   3. Details of person subject to the notification obligation Name Pfizer Inc.   New York   Country of registered office (if applicable) United States of America   4. Details of the shareholder Name Country of registered office London United Kingdom Guaranty Nominees Limited London United Kingdom   5. Date on which the threshold was crossed or reached 03-Oct-2024   6. Date on which Issuer notified 03-Oct-2024   7. Total positions of person(s) subject to the notification obligation   % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached 15.040000 0.000000 15.040000 Position of previous notification (if applicable) 22.580000 0.000000 22.580000     8. Notified details of the resulting situation on the date on which the threshold was crossed or reached   8A. Voting rights attached to shares Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1) Ordinary Shares GB00BMX86B70 967251860 10.680000 Restricted ADSs 394457904   4.360000 Sub Total 8.A 15.040000%   8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights           Sub Total 8.B1         8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b)) Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights             Sub Total 8.B2         9. Information in relation to the person subject to the notification obligation 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.   Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold             10. In case of proxy voting Name of the proxy holder     The number and % of voting rights held     The date until which the voting rights will be held     11. Additional Information   This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").Pfizer sold 640,000,000 Haleon ordinary shares ("Ordinary Shares") pursuant to a secondary offering announced on 30 September 2024. In connection with the offering, and in addition to the 640,000,000 Ordinary Shares in the offering, Pfizer sold 60,526,315 Ordinary Shares to Haleon in an off-market sale in accordance with the terms of a share purchase deed between Haleon and Pfizer that was pre